MAPT and early-onset autosomal dominant Alzheimer disease: In vitro studies have demonstrated the ability of GSK3β to phosphorylate over 40 residues of tau [121, 129–132], most of which are present in tauopathies such as Alzheimer’s disease and CTE, including Thr231, Ser202 and Ser205.